RxDoctor Payments Data

Thomas Evans, MD

Family Medicine · Tulare, CANPI 1033209846

Payments from drug & device makers

$24,539in general payments, 2019–2025

Across 834 payments — averaging $29.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • Lilly USA, LLC$2K
  • Amgen$2K
  • AbbVie$2K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • plus $11K from 41 others

What the payments were for

  • Food & beverage$24,447100%
  • Education$920%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,539 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$121,910
Medicare patients
244
Services billed
1,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin112$102,271
OzempicSemaglutide81$81,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$55,145
FarxigaDapagliflozin Propanediol45$45,438
EliquisApixaban35$32,946
Bydureon BciseExenatide Microspheres23$32,506
LinzessLinaclotide33$17,598
XareltoRivaroxaban11$12,595
Synjardy XrEmpagliflozin/Metformin Hcl18$11,262
Combivent RespimatIpratropium/Albuterol Sulfate17$8,982
Nucynta ErTapentadol Hcl11$8,338
Xtampza ErOxycodone Myristate12$6,490
Xigduo XrDapaglifloz Propaned/Metformin14$6,234
Janumet XrSitagliptin Phos/Metformin Hcl15$5,159
RytaryCarbidopa/Levodopa11$4,810

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat$1,383$122,515147 claims
Novo NordiskOzempic$1,413$81,94581 claims
GSKTrelegy Ellipta$1,280$55,14572 claims
AstraZenecaFarxiga$4,920$45,43845 claims
PfizerEliquis$871$32,94635 claims
AbbVieLinzess$1,933$17,59833 claims
Johnson & JohnsonXarelto$505$12,59511 claims
Amneal Pharmaceuticals LLCRytary, Levothyroxine Sodium$125$7,974434 claims
MerckJanumet Xr$882$5,15915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Tulare

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →